Who we are

Right beside people living with diabetes.

Born in Grenoble from medical research, Diabeloop is a pioneer in therapeutic AI that automates insulin delivery.

Discover our tech
A woman running, wearing a glucose sensor on her arm.
Real-world data
15,000+ Cumulative European patients
DBLG2 · Regulatory status
FDA & CE CE-marked under EU MDR & FDA 510(k)-cleared algorithm
DBLG1 · vs. prior therapy
+17.3 pts1 Mean increase in time in range
(70–180 mg/dL) Percentage points · 62 adults, 3-month follow-up
DBLG1 · European cohort
1.3%1 Mean time below range
(< 70 mg/dL) 6,658 adults, real-world cohort

Clinical results relate to DBLG1. The two figures above were observed in different study populations and are not results from a DBLG2 study. Individual outcomes may vary.

Study details & reference [1]

Time in range: the review reports an increase of 17.3 percentage points, from 54.9% to 72.2%, in a Spanish cohort of 62 adults using DBLG1, compared with their prior therapy.

Time below range: the review reports a mean of 1.3% below 70 mg/dL in a separate European cohort of 6,658 adults using DBLG1. This value is not from the Spanish cohort.

[1] Benhamou P-Y, Adenis A, Lablanche S, et al. First Generation of a Modular Interoperable Closed-Loop System for Automated Insulin Delivery in Patients With Type 1 Diabetes: Lessons From Trials and Real-Life Data. Journal of Diabetes Science and Technology. 2023;17(6):1433–1439. Tables 1–2 and accompanying text. DOI: 10.1177/19322968231186976.

Read the publication (opens in a new tab)

The approach behind Diabeloop

Built with people.
Grounded in science.

An algorithm is only part of the story. Diabeloop brings together lived experience, medical expertise and engineering to develop automated insulin delivery.

Built on shared expertise

People Lived experience
Clinical expertise Medical perspective
Engineering Technology & design
Diabeloop Built together
Different expertise. A shared focus on life with diabetes.

Start with the person.

Diabeloop involves people living with diabetes in defining the needs its technology should address.

A concrete evolution: DBLG2 brings the algorithm from a dedicated handset to a compatible personal smartphone. Read more ↗

Connect medicine and engineering.

The challenge spans clinical needs, algorithms and the design of a medical device. Diabeloop’s origins bring these disciplines together.

Medical research initiated at CERITD.
Technology developed with the CEA-Leti through a shared research laboratory.

Put ideas to the test.

Clinical studies are part of the path from an algorithm to a medical device. For DBLG1, development included a multicentre validation programme.

12 French university hospitals
involved in the DBLG1 validation study completed in 2017.

Leadership & governance

The people
behind Diabeloop.

Meet our management team, board of directors and observers.

The team leading Diabeloop.

Portrait of François Miceli

François Miceli

Chief Executive Officer

Portrait of Erik Huneker

Erik Huneker

Co-founder, Director Science & QARA

Pierre-Yves Benhamou

Chief Medical Officer

Eric Bazin

Chief Financial Officer

Arnaud Guillet

Chief Business Officer

Franck Fourel

Director of Research & Development

Emilie Pinto

Director of Human Resources

Board of directors.

Portrait of François Miceli

François Miceli

Chairman and CEO, Diabeloop

Portrait of Catherine Dunand

Catherine Dunand

CEO, Cemag Invest

C. Hart

General Partner, Supernova Invest

A. Henin

Independent Investor

V. Huot

Partner, Head of Venture Digital Health, LBO France

Observers.

P. Roussel

CEO, Agiradom

I. Bou Antoun

Investment Director, UI Investissement

S. Woynar

Managing Director, LBO France

B. Praud

Investment Director, Innovacom

Our ecosystem

An ecosystem that
supports innovation.

Institutions, funding programmes and innovation networks that have been part of Diabeloop’s journey.

  • European Union

    Horizon 2020

  • Bpifrance

    Financing support

  • La French Tech

    French Tech 120 · 2020

  • France Biotech

    Healthtech network

  • Minalogic

    Digital innovation cluster

  • Lyonbiopôle

    Health innovation cluster

  • EIT Health

    European health innovation

  • Medtech4Health

    Medtech innovation programme

Diabeloop received funding from the European Union’s Horizon 2020 programme under grant agreement No. 849157.

Our next chapter, together

Let’s move
diabetes care
forward.

It starts with people, ideas and a conversation. What could we build together?

Start a conversation.

Have a project or a partnership in mind? Get in touch with our team.

Contact our team

Bring your perspective.

Want to contribute your skills to Diabeloop? Explore careers with us.

Explore careers

Diabeloop · Innovating for life